Literature DB >> 25934614

Biliary Epithelial Cells Are Not the Predominant Source of Hepatic CXCL12.

Yedidya Saiman1, Tatsuki Sugiyama2, Noa Simchoni3, Carlo Spirli4, Meena B Bansal5.   

Abstract

Hepatic expression levels of CXCL12, a chemokine important in inflammatory and stem cell recruitment, and its receptor, C-X-C chemokine receptor 4, are increased during all forms of liver injury. CXCL12 is expressed by both parenchymal and nonparenchymal hepatic cells, and on the basis of immunohistochemistry, biliary epithelial cells (BECs) are thought to be a predominant source of hepatic CXCL12, thereby promoting periportal recruitment of C-X-C chemokine receptor 4-expressing lymphocytes. Our study aims to show that BECs may, in fact, not be the predominant source of hepatic CXCL12. We measured CXCL12 secretion and expression from human and murine BECs using enzyme-linked immunosorbent assay and Western blot analysis from cell culture supernatants and whole cell lysates, respectively, whereas CXCL12 expression in murine livers was analyzed in a Cxcl12-Gfp reporter mouse. Cell culture supernatants and whole cell lysates from BECs failed to demonstrate their expression of CXCL12. Furthermore, we confirmed these results with a Cxcl12-Gfp reporter mouse in which green fluorescent protein expression is notably absent from BECs. Interestingly, on the basis of green fluorescent protein expression, we demonstrate a population of CXCL12-expressing cells within the portal tract that are distinct, yet intimately associated with BECs. These findings indicate that BECs are not a predominant source of CXCL12.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934614      PMCID: PMC4483462          DOI: 10.1016/j.ajpath.2015.03.006

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT.

Authors:  Masanobu Maruyama; Naoya Kobayashi; Karen A Westerman; Masakiyo Sakaguchi; Jean E Allain; Toshinori Totsugawa; Teru Okitsu; Takuya Fukazawa; Anne Weber; Donna B Stolz; Philippe Leboulch; Noriaki Tanaka
Journal:  Transplantation       Date:  2004-02-15       Impact factor: 4.939

2.  Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.

Authors:  Muthu K Shanmugam; Kanjoormana A Manu; Tina H Ong; Lalitha Ramachandran; Rohit Surana; Pradeep Bist; Lina H K Lim; Alan Prem Kumar; Kam M Hui; Gautam Sethi
Journal:  Int J Cancer       Date:  2011-07-20       Impact factor: 7.396

3.  Differential location of hemopoietic colonies within liver acini of postnatal and phenylhydrazine-treated adult mice.

Authors:  E Barberá-Guillem; R Ayala; F Vidal-Vanaclocha
Journal:  Hepatology       Date:  1989-01       Impact factor: 17.425

4.  A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo.

Authors:  Toshiaki Ara; Manami Itoi; Kenji Kawabata; Takeshi Egawa; Koji Tokoyoda; Tatsuki Sugiyama; Nobutaka Fujii; Takashi Amagai; Takashi Nagasawa
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

5.  Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat.

Authors:  Philippe Mavier; Nadine Martin; Dominique Couchie; Anne-Marie Préaux; Yannick Laperche; Elie Serge Zafrani
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.

Authors:  Jinsheng Guo; Johnny Loke; Feng Zheng; Feng Hong; Steven Yea; Masayuki Fukata; Mirko Tarocchi; Olivia T Abar; Hongjin Huang; John J Sninsky; Scott L Friedman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

8.  Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus.

Authors:  Ori Wald; Orit Pappo; Rifaat Safadi; Michal Dagan-Berger; Katia Beider; Hanna Wald; Suzanna Franitza; Ido Weiss; Shani Avniel; Pal Boaz; Jacob Hanna; Gidi Zamir; Ahmed Eid; Ofer Mandelboim; Ulrich Spengler; Eithan Galun; Amnon Peled
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

9.  CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance.

Authors:  Adam Greenbaum; Yen-Michael S Hsu; Ryan B Day; Laura G Schuettpelz; Matthew J Christopher; Joshua N Borgerding; Takashi Nagasawa; Daniel C Link
Journal:  Nature       Date:  2013-02-24       Impact factor: 49.962

10.  Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

Authors:  Bi-Sen Ding; Zhongwei Cao; Raphael Lis; Daniel J Nolan; Peipei Guo; Michael Simons; Mark E Penfold; Koji Shido; Sina Y Rabbany; Shahin Rafii
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  2 in total

Review 1.  Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are key.

Authors:  Meena B Bansal
Journal:  Hepatol Int       Date:  2016-08-30       Impact factor: 6.047

Review 2.  The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review.

Authors:  Alican Özkan; Danielle Stolley; Erik N K Cressman; Matthew McMillin; Sharon DeMorrow; Thomas E Yankeelov; Marissa Nichole Rylander
Journal:  Micromachines (Basel)       Date:  2020-05-09       Impact factor: 2.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.